Evidence map›Paper›PMID 29304083›Full record

Trial reportPloS one2018

Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission.

Kristina Adachi, Jiahong Xu, Nava Yeganeh, Margaret Camarca, Mariza G Morgado, D Heather Watts, Lynne M Mofenson, Valdilea G Veloso, Jose Henrique Pilotto, Esau Joao and 18 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00099359 (Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00099359 phase3completednot on this map

Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission

TypeinterventionalSponsorEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Ran2004 to 2011Enrolled1,735ConditionsDisease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV InfectionsArmsZidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV)
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Sexually Transmitted Infections in Pregnant People With Human Immunodeficiency Virus: Temporal Trends, Demographic Correlates, and Association With Preterm Birth.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Significant Associations betweenInfectious diseases in obstetrics and gynecology · 2022
    Article
  13. Article
  14. Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Article
  20. Sexually transmitted infections in pregnant women from sub-Saharan Africa.Southern African journal of infectious diseases · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 19 institutions in 4 countries.

Kristina AdachiDavid Geffen UCLA School of Medicine, Los Angeles, CA, United States of America.ORCID 0000-0002-5796-2767
Jiahong XuWestat, Rockville, MD, United States of America.
Nava YeganehDavid Geffen UCLA School of Medicine, Los Angeles, CA, United States of America.
Margaret CamarcaWestat, Rockville, MD, United States of America.
Mariza G MorgadoFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
D Heather WattsOffice of the Global AIDS Coordinator, U.S. Department of State, Washington D.C., United States of America.
Lynne M MofensonElizabeth Glaser Pediatric AIDS Foundation, Washington D.C., United States of America.
Valdilea G VelosoFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Jose Henrique PilottoHospital Geral de Nova Iguaçu, Nova Iguaçu, RJ, Brazil.
Esau JoaoHospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil.
Glenda GraySAMRC and Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.
Gerhard TheronStellenbosch University/Tygerberg Hospital, Cape Town, South Africa.
Breno SantosHospital Conceicao, Porto Alegre, RS, Brazil.
Rosana FonsecaHospital Femina, Porto Alegre, RS, Brazil.
Regis KreitchmannIrmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil.
Jorge PintoFederal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Marisa M Mussi-PinhataRibeirão Preto Medical School, University of São Paulo, São Paulo, SP, Brazil.
Mariana CeriottoFoundation for Maternal and Infant Health (FUNDASAMIN), Buenos Aires, Argentina.
Daisy Maria MachadoEscola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Yvonne J BrysonDavid Geffen UCLA School of Medicine, Los Angeles, CA, United States of America.
Beatriz GrinsztejnFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Jack MoyeEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States of America.
Jeffrey D KlausnerDavid Geffen UCLA School of Medicine, Los Angeles, CA, United States of America.
Claire C BristowUCSD School of Medicine, La Jolla, CA, United States of America.
Ruth DickoverUC Davis School of Medicine, Davis, CA, United States of America.
Mark MirochnickBoston University School of Medicine, Boston, MA, United States of America.
Karin Nielsen-SainesDavid Geffen UCLA School of Medicine, Los Angeles, CA, United States of America.
NICHD HPTN 040 Study Team
University of California, Los Angeles · USFundação Oswaldo Cruz · BRWestat (United States) · USBoston University · USElizabeth Glaser Pediatric AIDS Foundation · USHospital Federal dos Servidores do Estado · BRHospital Nossa Senhora da Conceição · BRInfant Foundation · ARIrmandade da Santa Casa de Misericórdia de São Paulo · BRNational Institutes of Health · USSouth African Medical Research Council · ZAStellenbosch University · ZAUnited States Department of State · USUniversidade de São Paulo · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal de São Paulo · BRUniversidade Iguaçu · BRUniversity of California, Davis · USUniversity of California San Diego · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORKU01AI047986 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRYSON, YVONNE J · 2000 to 2006
$13.3M
TRIPAI: An innovative way to improve the health of infants by including fathers during prenatal careK23AI118584 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YEGANEH, NAVA · 2015 to 2019
$968k
NIAID NIH HHS K23 AI118584NIAID NIH HHS P30 AI028697NIAID NIH HHS U01 AI047986NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI069424NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI106716NICHD NIH HHS HHSN267200800001CNICHD NIH HHS HHSN275201300003CNIDDK NIH HHS HHSN267200800001G
6 · The paper itself

Abstract

backgroundSexually transmitted infections (STIs) including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Treponema pallidum (TP), and cytomegalovirus (CMV) may lead to adverse pregnancy and infant outcomes. The role of combined maternal STIs in HIV mother-to-child transmission (MTCT) was evaluated in mother-infant pairs from NICHD HPTN 040. METHODOLOGY: Urine samples from HIV-infected pregnant women during labor were tested by polymerase chain reaction (PCR) for CT, NG, and CMV. Infant HIV infection was determined by serial HIV DNA PCR testing. Maternal syphilis was tested by VDRL and confirmatory treponemal antibodies.

resultsA total of 899 mother-infant pairs were evaluated. Over 30% had at least one of the following infections (TP, CT, NG, and/or CMV) detected at the time of delivery. High rates of TP (8.7%), CT (17.8%), NG (4%), and CMV (6.3%) were observed. HIV MTCT was 9.1% (n = 82 infants). HIV MTCT was 12.5%, 10.3%, 11.1%, and 26.3% among infants born to women with CT, TP, NG or CMV respectively. Forty-two percent of HIV-infected infants were born to women with at least one of these 4 infections. Women with these infections were nearly twice as likely to have an HIV-infected infant (aOR 1.9, 95% CI 1.1-3.0), particularly those with 2 STIs (aOR 3.4, 95% CI 1.5-7.7). Individually, maternal CMV (aOR 4.4 1.5-13.0) and infant congenital CMV (OR 4.1, 95% CI 2.2-7.8) but not other STIs (TP, CT, or NG) were associated with an increased risk of HIV MTCT.

conclusionHIV-infected pregnant women identified during labor are at high risk for STIs. Co-infection with STIs including CMV nearly doubles HIV MTCT risk. CMV infection appears to confer the largest risk of HIV MTCT.

trial registrationNCT00099359.

Indexed as

Infectious Disease Transmission, VerticalPregnancy Complications, InfectiousAdolescentAdultChlamydia InfectionsChlamydia trachomatisCross-Sectional StudiesFemaleGonorrheaHIV InfectionsHumansInfantInfant, NewbornMiddle AgedPregnancyRetrospective Studies

Identifiers

PMID29304083
PMCPMC5755782
OpenAlexW2782537207

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.